Professor Wang's team has developed a novel PD-L1-targeted chimeric switch receptor (PD-L1.BB CSR) aimed at augmenting CAR-T cells' ability to identify and eliminate tumor cells, thereby enhancing therapeutic efficacy (Fig. 3B) [65]. The gene discussed is CD274; the disease is neoplasm.